CN112592395A - Construction, preparation and application of plasmodium falciparum RIFIN recombinant protein PfRIFIN-54 - Google Patents
Construction, preparation and application of plasmodium falciparum RIFIN recombinant protein PfRIFIN-54 Download PDFInfo
- Publication number
- CN112592395A CN112592395A CN202011460834.2A CN202011460834A CN112592395A CN 112592395 A CN112592395 A CN 112592395A CN 202011460834 A CN202011460834 A CN 202011460834A CN 112592395 A CN112592395 A CN 112592395A
- Authority
- CN
- China
- Prior art keywords
- plasmodium falciparum
- rifin
- protein
- gene
- pfrifin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108700027811 Plasmodium falciparum RIFIN Proteins 0.000 title claims abstract description 74
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 title claims abstract description 22
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 title claims abstract description 22
- 238000002360 preparation method Methods 0.000 title claims abstract description 20
- 238000010276 construction Methods 0.000 title description 8
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 75
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 46
- 239000013612 plasmid Substances 0.000 claims abstract description 39
- 241000223960 Plasmodium falciparum Species 0.000 claims abstract description 30
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 3
- 230000014509 gene expression Effects 0.000 claims description 23
- 238000000034 method Methods 0.000 claims description 19
- 238000012408 PCR amplification Methods 0.000 claims description 13
- 239000012634 fragment Substances 0.000 claims description 11
- 238000001262 western blot Methods 0.000 claims description 11
- 241000209140 Triticum Species 0.000 claims description 9
- 235000021307 Triticum Nutrition 0.000 claims description 9
- 241000588724 Escherichia coli Species 0.000 claims description 8
- 238000006243 chemical reaction Methods 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 8
- 238000012163 sequencing technique Methods 0.000 claims description 7
- 230000001580 bacterial effect Effects 0.000 claims description 6
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 5
- 239000013600 plasmid vector Substances 0.000 claims description 5
- 238000011144 upstream manufacturing Methods 0.000 claims description 4
- 241000620209 Escherichia coli DH5[alpha] Species 0.000 claims description 3
- 239000006142 Luria-Bertani Agar Substances 0.000 claims description 3
- 241000224016 Plasmodium Species 0.000 claims description 3
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 claims description 3
- 229960000723 ampicillin Drugs 0.000 claims description 3
- 238000000137 annealing Methods 0.000 claims description 3
- 238000004925 denaturation Methods 0.000 claims description 3
- 230000036425 denaturation Effects 0.000 claims description 3
- 238000001976 enzyme digestion Methods 0.000 claims description 3
- 239000002609 medium Substances 0.000 claims description 3
- 238000012257 pre-denaturation Methods 0.000 claims description 3
- 230000035939 shock Effects 0.000 claims description 3
- 238000000246 agarose gel electrophoresis Methods 0.000 claims description 2
- 230000000295 complement effect Effects 0.000 claims description 2
- 239000002773 nucleotide Substances 0.000 claims description 2
- 125000003729 nucleotide group Chemical group 0.000 claims description 2
- 230000009465 prokaryotic expression Effects 0.000 claims description 2
- 238000000746 purification Methods 0.000 claims 1
- 238000011084 recovery Methods 0.000 claims 1
- 210000002966 serum Anatomy 0.000 abstract description 28
- 230000036046 immunoreaction Effects 0.000 abstract description 12
- 238000010367 cloning Methods 0.000 description 8
- 206010035500 Plasmodium falciparum infection Diseases 0.000 description 7
- 239000012528 membrane Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 239000002033 PVDF binder Substances 0.000 description 6
- 239000006180 TBST buffer Substances 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 201000004792 malaria Diseases 0.000 description 6
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 230000000903 blocking effect Effects 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 210000003743 erythrocyte Anatomy 0.000 description 5
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 4
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 4
- 208000002476 Falciparum Malaria Diseases 0.000 description 4
- 201000011336 Plasmodium falciparum malaria Diseases 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 230000017188 evasion or tolerance of host immune response Effects 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000013598 vector Substances 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 102100020943 Leukocyte-associated immunoglobulin-like receptor 1 Human genes 0.000 description 3
- 150000001413 amino acids Chemical group 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 238000007865 diluting Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 238000010200 validation analysis Methods 0.000 description 3
- 238000012795 verification Methods 0.000 description 3
- ZAINTDRBUHCDPZ-UHFFFAOYSA-M Alexa Fluor 546 Chemical compound [H+].[Na+].CC1CC(C)(C)NC(C(=C2OC3=C(C4=NC(C)(C)CC(C)C4=CC3=3)S([O-])(=O)=O)S([O-])(=O)=O)=C1C=C2C=3C(C(=C(Cl)C=1Cl)C(O)=O)=C(Cl)C=1SCC(=O)NCCCCCC(=O)ON1C(=O)CCC1=O ZAINTDRBUHCDPZ-UHFFFAOYSA-M 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 239000012880 LB liquid culture medium Substances 0.000 description 2
- 108010017736 Leukocyte Immunoglobulin-like Receptor B1 Proteins 0.000 description 2
- 102100025584 Leukocyte immunoglobulin-like receptor subfamily B member 1 Human genes 0.000 description 2
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 2
- PMTWIUBUQRGCSB-FXQIFTODSA-N Ser-Val-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(O)=O PMTWIUBUQRGCSB-FXQIFTODSA-N 0.000 description 2
- KOSRFJWDECSPRO-UHFFFAOYSA-N alpha-L-glutamyl-L-glutamic acid Natural products OC(=O)CCC(N)C(=O)NC(CCC(O)=O)C(O)=O KOSRFJWDECSPRO-UHFFFAOYSA-N 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000005875 antibody response Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 108010055341 glutamyl-glutamic acid Proteins 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 108010044374 isoleucyl-tyrosine Proteins 0.000 description 2
- 108010025001 leukocyte-associated immunoglobulin-like receptor 1 Proteins 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000002493 microarray Methods 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 230000003950 pathogenic mechanism Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000011535 reaction buffer Substances 0.000 description 2
- 210000005166 vasculature Anatomy 0.000 description 2
- HHGYNJRJIINWAK-FXQIFTODSA-N Ala-Ala-Arg Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N HHGYNJRJIINWAK-FXQIFTODSA-N 0.000 description 1
- LSLIRHLIUDVNBN-CIUDSAMLSA-N Ala-Asp-Lys Chemical compound C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CCCCN LSLIRHLIUDVNBN-CIUDSAMLSA-N 0.000 description 1
- LGFCAXJBAZESCF-ACZMJKKPSA-N Ala-Gln-Ala Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(O)=O LGFCAXJBAZESCF-ACZMJKKPSA-N 0.000 description 1
- PAIHPOGPJVUFJY-WDSKDSINSA-N Ala-Glu-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O PAIHPOGPJVUFJY-WDSKDSINSA-N 0.000 description 1
- BTBUEVAGZCKULD-XPUUQOCRSA-N Ala-Gly-His Chemical compound C[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC1=CN=CN1 BTBUEVAGZCKULD-XPUUQOCRSA-N 0.000 description 1
- AJBVYEYZVYPFCF-CIUDSAMLSA-N Ala-Lys-Asn Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O AJBVYEYZVYPFCF-CIUDSAMLSA-N 0.000 description 1
- CNQAFFMNJIQYGX-DRZSPHRISA-N Ala-Phe-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)C)CC1=CC=CC=C1 CNQAFFMNJIQYGX-DRZSPHRISA-N 0.000 description 1
- KUFVXLQLDHJVOG-SHGPDSBTSA-N Ala-Thr-Thr Chemical compound C[C@H]([C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)[C@H](C)N)O KUFVXLQLDHJVOG-SHGPDSBTSA-N 0.000 description 1
- 239000012099 Alexa Fluor family Substances 0.000 description 1
- MUXONAMCEUBVGA-DCAQKATOSA-N Arg-Arg-Gln Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(N)=O)C(O)=O MUXONAMCEUBVGA-DCAQKATOSA-N 0.000 description 1
- BTJVOUQWFXABOI-IHRRRGAJSA-N Arg-Lys-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCCNC(N)=N BTJVOUQWFXABOI-IHRRRGAJSA-N 0.000 description 1
- VUGWHBXPMAHEGZ-SRVKXCTJSA-N Arg-Pro-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCCN=C(N)N VUGWHBXPMAHEGZ-SRVKXCTJSA-N 0.000 description 1
- KMFPQTITXUKJOV-DCAQKATOSA-N Arg-Ser-Leu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O KMFPQTITXUKJOV-DCAQKATOSA-N 0.000 description 1
- QMQZYILAWUOLPV-JYJNAYRXSA-N Arg-Tyr-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)CC1=CC=C(O)C=C1 QMQZYILAWUOLPV-JYJNAYRXSA-N 0.000 description 1
- PIWWUBYJNONVTJ-ZLUOBGJFSA-N Asn-Asp-Asn Chemical compound C([C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(=O)N)C(=O)O)N)C(=O)N PIWWUBYJNONVTJ-ZLUOBGJFSA-N 0.000 description 1
- ZDOQDYFZNGASEY-BIIVOSGPSA-N Asn-Asp-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)N)N)C(=O)O ZDOQDYFZNGASEY-BIIVOSGPSA-N 0.000 description 1
- VWJFQGXPYOPXJH-ZLUOBGJFSA-N Asn-Cys-Asp Chemical compound C([C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(=O)O)C(=O)O)N)C(=O)N VWJFQGXPYOPXJH-ZLUOBGJFSA-N 0.000 description 1
- XBQSLMACWDXWLJ-GHCJXIJMSA-N Asp-Ala-Ile Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O XBQSLMACWDXWLJ-GHCJXIJMSA-N 0.000 description 1
- NYLBGYLHBDFRHL-VEVYYDQMSA-N Asp-Arg-Thr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(O)=O NYLBGYLHBDFRHL-VEVYYDQMSA-N 0.000 description 1
- IJHUZMGJRGNXIW-CIUDSAMLSA-N Asp-Glu-Arg Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O IJHUZMGJRGNXIW-CIUDSAMLSA-N 0.000 description 1
- QNFRBNZGVVKBNJ-PEFMBERDSA-N Asp-Ile-Gln Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC(=O)O)N QNFRBNZGVVKBNJ-PEFMBERDSA-N 0.000 description 1
- GKWFMNNNYZHJHV-SRVKXCTJSA-N Asp-Lys-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CC(O)=O GKWFMNNNYZHJHV-SRVKXCTJSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 235000019750 Crude protein Nutrition 0.000 description 1
- UPJGYXRAPJWIHD-CIUDSAMLSA-N Cys-Asn-Leu Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(O)=O UPJGYXRAPJWIHD-CIUDSAMLSA-N 0.000 description 1
- KABHAOSDMIYXTR-GUBZILKMSA-N Cys-Glu-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CS)N KABHAOSDMIYXTR-GUBZILKMSA-N 0.000 description 1
- YKKHFPGOZXQAGK-QWRGUYRKSA-N Cys-Gly-Tyr Chemical compound SC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 YKKHFPGOZXQAGK-QWRGUYRKSA-N 0.000 description 1
- ABLJDBFJPUWQQB-DCAQKATOSA-N Cys-Leu-Arg Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)NC(=O)[C@H](CS)N ABLJDBFJPUWQQB-DCAQKATOSA-N 0.000 description 1
- 238000012270 DNA recombination Methods 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 206010071602 Genetic polymorphism Diseases 0.000 description 1
- JHPFPROFOAJRFN-IHRRRGAJSA-N Gln-Glu-Tyr Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)N)N)O JHPFPROFOAJRFN-IHRRRGAJSA-N 0.000 description 1
- QKCZZAZNMMVICF-DCAQKATOSA-N Gln-Leu-Glu Chemical compound NC(=O)CC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O QKCZZAZNMMVICF-DCAQKATOSA-N 0.000 description 1
- LURQDGKYBFWWJA-MNXVOIDGSA-N Gln-Lys-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(=O)N)N LURQDGKYBFWWJA-MNXVOIDGSA-N 0.000 description 1
- KFHASAPTUOASQN-JYJNAYRXSA-N Gln-Phe-His Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC2=CN=CN2)C(=O)O)NC(=O)[C@H](CCC(=O)N)N KFHASAPTUOASQN-JYJNAYRXSA-N 0.000 description 1
- PIUPHASDUFSHTF-CIUDSAMLSA-N Gln-Pro-Asn Chemical compound C1C[C@H](N(C1)C(=O)[C@H](CCC(=O)N)N)C(=O)N[C@@H](CC(=O)N)C(=O)O PIUPHASDUFSHTF-CIUDSAMLSA-N 0.000 description 1
- AKDOUBMVLRCHBD-SIUGBPQLSA-N Gln-Tyr-Ile Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O AKDOUBMVLRCHBD-SIUGBPQLSA-N 0.000 description 1
- NCWOMXABNYEPLY-NRPADANISA-N Glu-Ala-Val Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(O)=O NCWOMXABNYEPLY-NRPADANISA-N 0.000 description 1
- NLKVNZUFDPWPNL-YUMQZZPRSA-N Glu-Arg-Gly Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O NLKVNZUFDPWPNL-YUMQZZPRSA-N 0.000 description 1
- QCMVGXDELYMZET-GLLZPBPUSA-N Glu-Thr-Glu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(O)=O QCMVGXDELYMZET-GLLZPBPUSA-N 0.000 description 1
- OCDLPQDYTJPWNG-YUMQZZPRSA-N Gly-Asn-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)CN OCDLPQDYTJPWNG-YUMQZZPRSA-N 0.000 description 1
- ITZOBNKQDZEOCE-NHCYSSNCSA-N Gly-Ile-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)CN ITZOBNKQDZEOCE-NHCYSSNCSA-N 0.000 description 1
- CCBIBMKQNXHNIN-ZETCQYMHSA-N Gly-Leu-Gly Chemical compound NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O CCBIBMKQNXHNIN-ZETCQYMHSA-N 0.000 description 1
- BMWFDYIYBAFROD-WPRPVWTQSA-N Gly-Pro-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)CN BMWFDYIYBAFROD-WPRPVWTQSA-N 0.000 description 1
- LLWQVJNHMYBLLK-CDMKHQONSA-N Gly-Thr-Phe Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O LLWQVJNHMYBLLK-CDMKHQONSA-N 0.000 description 1
- HVCRQRQPIIRNLY-IUCAKERBSA-N His-Gln-Gly Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)NCC(=O)O)N HVCRQRQPIIRNLY-IUCAKERBSA-N 0.000 description 1
- UPJODPVSKKWGDQ-KLHWPWHYSA-N His-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC2=CN=CN2)N)O UPJODPVSKKWGDQ-KLHWPWHYSA-N 0.000 description 1
- UWNUQPZUSRFIIN-JUKXBJQTSA-N His-Tyr-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CC2=CN=CN2)N UWNUQPZUSRFIIN-JUKXBJQTSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001138062 Homo sapiens Leukocyte-associated immunoglobulin-like receptor 1 Proteins 0.000 description 1
- JRHFQUPIZOYKQP-KBIXCLLPSA-N Ile-Ala-Glu Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCC(O)=O JRHFQUPIZOYKQP-KBIXCLLPSA-N 0.000 description 1
- LDRALPZEVHVXEK-KBIXCLLPSA-N Ile-Cys-Glu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N LDRALPZEVHVXEK-KBIXCLLPSA-N 0.000 description 1
- AWTDTFXPVCTHAK-BJDJZHNGSA-N Ile-Cys-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCCN)C(=O)O)N AWTDTFXPVCTHAK-BJDJZHNGSA-N 0.000 description 1
- PWDSHAAAFXISLE-SXTJYALSSA-N Ile-Ile-Asp Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(O)=O PWDSHAAAFXISLE-SXTJYALSSA-N 0.000 description 1
- TVYWVSJGSHQWMT-AJNGGQMLSA-N Ile-Leu-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)O)N TVYWVSJGSHQWMT-AJNGGQMLSA-N 0.000 description 1
- GVNNAHIRSDRIII-AJNGGQMLSA-N Ile-Lys-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)O)N GVNNAHIRSDRIII-AJNGGQMLSA-N 0.000 description 1
- HZVRQFKRALAMQS-SLBDDTMCSA-N Ile-Trp-Asp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(=O)O)C(=O)O)N HZVRQFKRALAMQS-SLBDDTMCSA-N 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- FADYJNXDPBKVCA-UHFFFAOYSA-N L-Phenylalanyl-L-lysin Natural products NCCCCC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 FADYJNXDPBKVCA-UHFFFAOYSA-N 0.000 description 1
- LZDNBBYBDGBADK-UHFFFAOYSA-N L-valyl-L-tryptophan Natural products C1=CC=C2C(CC(NC(=O)C(N)C(C)C)C(O)=O)=CNC2=C1 LZDNBBYBDGBADK-UHFFFAOYSA-N 0.000 description 1
- 241000880493 Leptailurus serval Species 0.000 description 1
- WNGVUZWBXZKQES-YUMQZZPRSA-N Leu-Ala-Gly Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C)C(=O)NCC(O)=O WNGVUZWBXZKQES-YUMQZZPRSA-N 0.000 description 1
- CLVUXCBGKUECIT-HJGDQZAQSA-N Leu-Asp-Thr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O CLVUXCBGKUECIT-HJGDQZAQSA-N 0.000 description 1
- KWURTLAFFDOTEQ-GUBZILKMSA-N Leu-Cys-Glu Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N KWURTLAFFDOTEQ-GUBZILKMSA-N 0.000 description 1
- ZTLGVASZOIKNIX-DCAQKATOSA-N Leu-Gln-Glu Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N ZTLGVASZOIKNIX-DCAQKATOSA-N 0.000 description 1
- CCQLQKZTXZBXTN-NHCYSSNCSA-N Leu-Gly-Ile Chemical compound [H]N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(O)=O CCQLQKZTXZBXTN-NHCYSSNCSA-N 0.000 description 1
- OHZIZVWQXJPBJS-IXOXFDKPSA-N Leu-His-Thr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O OHZIZVWQXJPBJS-IXOXFDKPSA-N 0.000 description 1
- VDIARPPNADFEAV-WEDXCCLWSA-N Leu-Thr-Gly Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O VDIARPPNADFEAV-WEDXCCLWSA-N 0.000 description 1
- RDIILCRAWOSDOQ-CIUDSAMLSA-N Lys-Cys-Asp Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(=O)O)C(=O)O)N RDIILCRAWOSDOQ-CIUDSAMLSA-N 0.000 description 1
- LPAJOCKCPRZEAG-MNXVOIDGSA-N Lys-Glu-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CCCCN LPAJOCKCPRZEAG-MNXVOIDGSA-N 0.000 description 1
- DCRWPTBMWMGADO-AVGNSLFASA-N Lys-Glu-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O DCRWPTBMWMGADO-AVGNSLFASA-N 0.000 description 1
- AIRZWUMAHCDDHR-KKUMJFAQSA-N Lys-Leu-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O AIRZWUMAHCDDHR-KKUMJFAQSA-N 0.000 description 1
- HVAUKHLDSDDROB-KKUMJFAQSA-N Lys-Lys-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O HVAUKHLDSDDROB-KKUMJFAQSA-N 0.000 description 1
- MTBLFIQZECOEBY-IHRRRGAJSA-N Lys-Met-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(O)=O MTBLFIQZECOEBY-IHRRRGAJSA-N 0.000 description 1
- LUAJJLPHUXPQLH-KKUMJFAQSA-N Lys-Phe-Ser Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CCCCN)N LUAJJLPHUXPQLH-KKUMJFAQSA-N 0.000 description 1
- IOQWIOPSKJOEKI-SRVKXCTJSA-N Lys-Ser-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O IOQWIOPSKJOEKI-SRVKXCTJSA-N 0.000 description 1
- UGCIQUYEJIEHKX-GVXVVHGQSA-N Lys-Val-Glu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O UGCIQUYEJIEHKX-GVXVVHGQSA-N 0.000 description 1
- OHMKUHXCDSCOMT-QXEWZRGKSA-N Met-Asn-Val Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(O)=O OHMKUHXCDSCOMT-QXEWZRGKSA-N 0.000 description 1
- WGBMNLCRYKSWAR-DCAQKATOSA-N Met-Asp-Lys Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CCCCN WGBMNLCRYKSWAR-DCAQKATOSA-N 0.000 description 1
- AWOMRHGUWFBDNU-ZPFDUUQYSA-N Met-Gln-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCSC)N AWOMRHGUWFBDNU-ZPFDUUQYSA-N 0.000 description 1
- GETCJHFFECHWHI-QXEWZRGKSA-N Met-Ile-Gly Chemical compound CC[C@H](C)[C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](CCSC)N GETCJHFFECHWHI-QXEWZRGKSA-N 0.000 description 1
- BEZJTLKUMFMITF-AVGNSLFASA-N Met-Lys-Arg Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(O)=O)CCCNC(N)=N BEZJTLKUMFMITF-AVGNSLFASA-N 0.000 description 1
- SITLTJHOQZFJGG-UHFFFAOYSA-N N-L-alpha-glutamyl-L-valine Natural products CC(C)C(C(O)=O)NC(=O)C(N)CCC(O)=O SITLTJHOQZFJGG-UHFFFAOYSA-N 0.000 description 1
- 108010066427 N-valyltryptophan Proteins 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- BKWJQWJPZMUWEG-LFSVMHDDSA-N Phe-Ala-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=CC=C1 BKWJQWJPZMUWEG-LFSVMHDDSA-N 0.000 description 1
- 241001505483 Plasmodium falciparum 3D7 Species 0.000 description 1
- 208000008601 Polycythemia Diseases 0.000 description 1
- ITUDDXVFGFEKPD-NAKRPEOUSA-N Pro-Ser-Ile Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O ITUDDXVFGFEKPD-NAKRPEOUSA-N 0.000 description 1
- MDAWMJUZHBQTBO-XGEHTFHBSA-N Pro-Thr-Cys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@@H]1CCCN1)O MDAWMJUZHBQTBO-XGEHTFHBSA-N 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- OSFZCEQJLWCIBG-BZSNNMDCSA-N Ser-Tyr-Tyr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O OSFZCEQJLWCIBG-BZSNNMDCSA-N 0.000 description 1
- MFQMZDPAZRZAPV-NAKRPEOUSA-N Ser-Val-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CO)N MFQMZDPAZRZAPV-NAKRPEOUSA-N 0.000 description 1
- 241001052560 Thallis Species 0.000 description 1
- OYTNZCBFDXGQGE-XQXXSGGOSA-N Thr-Gln-Ala Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](C)C(=O)O)N)O OYTNZCBFDXGQGE-XQXXSGGOSA-N 0.000 description 1
- QILPDQCTQZDHFM-HJGDQZAQSA-N Thr-Gln-Arg Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O QILPDQCTQZDHFM-HJGDQZAQSA-N 0.000 description 1
- WPAKPLPGQNUXGN-OSUNSFLBSA-N Thr-Ile-Arg Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O WPAKPLPGQNUXGN-OSUNSFLBSA-N 0.000 description 1
- JWQNAFHCXKVZKZ-UVOCVTCTSA-N Thr-Lys-Thr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O JWQNAFHCXKVZKZ-UVOCVTCTSA-N 0.000 description 1
- DXPURPNJDFCKKO-RHYQMDGZSA-N Thr-Lys-Val Chemical compound CC(C)[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)[C@@H](C)O)C(O)=O DXPURPNJDFCKKO-RHYQMDGZSA-N 0.000 description 1
- JAJOFWABAUKAEJ-QTKMDUPCSA-N Thr-Pro-His Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC2=CN=CN2)C(=O)O)N)O JAJOFWABAUKAEJ-QTKMDUPCSA-N 0.000 description 1
- KERCOYANYUPLHJ-XGEHTFHBSA-N Thr-Pro-Ser Chemical compound C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O KERCOYANYUPLHJ-XGEHTFHBSA-N 0.000 description 1
- NBIIPOKZPUGATB-BWBBJGPYSA-N Thr-Ser-Cys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)O)N)O NBIIPOKZPUGATB-BWBBJGPYSA-N 0.000 description 1
- WKQNLTQSCYXKQK-VFAJRCTISA-N Trp-Lys-Thr Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O WKQNLTQSCYXKQK-VFAJRCTISA-N 0.000 description 1
- GYKDRHDMGQUZPU-MGHWNKPDSA-N Tyr-Lys-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC1=CC=C(C=C1)O)N GYKDRHDMGQUZPU-MGHWNKPDSA-N 0.000 description 1
- FGVFBDZSGQTYQX-UFYCRDLUSA-N Tyr-Phe-Val Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(O)=O FGVFBDZSGQTYQX-UFYCRDLUSA-N 0.000 description 1
- OBKOPLHSRDATFO-XHSDSOJGSA-N Tyr-Val-Pro Chemical compound CC(C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC2=CC=C(C=C2)O)N OBKOPLHSRDATFO-XHSDSOJGSA-N 0.000 description 1
- ZLFHAAGHGQBQQN-GUBZILKMSA-N Val-Ala-Pro Natural products CC(C)[C@H](N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O ZLFHAAGHGQBQQN-GUBZILKMSA-N 0.000 description 1
- DBOXBUDEAJVKRE-LSJOCFKGSA-N Val-Asn-Val Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](C(C)C)C(=O)O)N DBOXBUDEAJVKRE-LSJOCFKGSA-N 0.000 description 1
- XGJLNBNZNMVJRS-NRPADANISA-N Val-Glu-Ala Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O XGJLNBNZNMVJRS-NRPADANISA-N 0.000 description 1
- LKUDRJSNRWVGMS-QSFUFRPTSA-N Val-Ile-Asp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](C(C)C)N LKUDRJSNRWVGMS-QSFUFRPTSA-N 0.000 description 1
- VHRLUTIMTDOVCG-PEDHHIEDSA-N Val-Ile-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)O)NC(=O)[C@H](C(C)C)N VHRLUTIMTDOVCG-PEDHHIEDSA-N 0.000 description 1
- OFQGGTGZTOTLGH-NHCYSSNCSA-N Val-Met-Gln Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N OFQGGTGZTOTLGH-NHCYSSNCSA-N 0.000 description 1
- CEKSLIVSNNGOKH-KZVJFYERSA-N Val-Thr-Ala Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](C)C(=O)O)NC(=O)[C@H](C(C)C)N)O CEKSLIVSNNGOKH-KZVJFYERSA-N 0.000 description 1
- PQSNETRGCRUOGP-KKHAAJSZSA-N Val-Thr-Asn Chemical compound CC(C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CC(N)=O PQSNETRGCRUOGP-KKHAAJSZSA-N 0.000 description 1
- IECQJCJNPJVUSB-IHRRRGAJSA-N Val-Tyr-Ser Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CO)C(O)=O IECQJCJNPJVUSB-IHRRRGAJSA-N 0.000 description 1
- DFQZDQPLWBSFEJ-LSJOCFKGSA-N Val-Val-Asn Chemical compound CC(C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(=O)N)C(=O)O)N DFQZDQPLWBSFEJ-LSJOCFKGSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 239000003430 antimalarial agent Substances 0.000 description 1
- 108010036533 arginylvaline Proteins 0.000 description 1
- 108010092854 aspartyllysine Proteins 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001506 fluorescence spectroscopy Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 108010049041 glutamylalanine Proteins 0.000 description 1
- 108010089804 glycyl-threonine Proteins 0.000 description 1
- 108010050848 glycylleucine Proteins 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 108010028295 histidylhistidine Proteins 0.000 description 1
- 108010025306 histidylleucine Proteins 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 108091008042 inhibitory receptors Proteins 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 108010091871 leucylmethionine Proteins 0.000 description 1
- 108010012058 leucyltyrosine Proteins 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 108010003700 lysyl aspartic acid Proteins 0.000 description 1
- 108010054155 lysyllysine Proteins 0.000 description 1
- 229940124735 malaria vaccine Drugs 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000004925 microvascular endothelial cell Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000003234 polygenic effect Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000006916 protein interaction Effects 0.000 description 1
- 239000012474 protein marker Substances 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 239000003161 ribonuclease inhibitor Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 108010048818 seryl-histidine Proteins 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 208000037972 tropical disease Diseases 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
- C07K14/445—Plasmodium
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/66—General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
- C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
- C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56905—Protozoa
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/44—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from protozoa
- G01N2333/445—Plasmodium
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2469/00—Immunoassays for the detection of microorganisms
- G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Plant Pathology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Crystallography & Structural Chemistry (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention relates to a plasmodium falciparum RIFIN recombinant protein coded by a plasmodium falciparum RIFIN gene PF3D7_0833100, which is named as PfRIFIN-54, the gene sequence of the recombinant protein is shown as SEQ ID No.1, and the amino acid sequence of the recombinant protein is shown as SEQ ID No. 4. A recombinant plasmid containing the gene PF3D7_ 0833100. A protein chip containing protein PfriFIN-54. The invention also discloses a preparation method of the plasmodium falciparum RIFIN recombinant protein. Compared with a control PfMSP1-42, the protein of the invention not only has better ability of specifically recognizing the serum of patients infected with plasmodium falciparum, but also shows obvious difference in the serum immunoreaction of severe patients and non-severe patients infected with plasmodium falciparum, and the positive rate of the immunoreaction of the serum of severe patients is obviously lower than that of the serum immunoreaction of non-severe patients.
Description
Technical Field
The invention belongs to the field of biological gene engineering, relates to a plasmodium falciparum RIFIN protein, and particularly relates to construction, preparation and application of a plasmodium falciparum RIFIN recombinant protein coded by a plasmodium falciparum RIFIN gene PF3D7_ 0833100.
Background
Genetic engineering (also known as gene splicing technology and DNA recombination technology) is based on molecular genetics as a theoretical basis, and by means of modern methods in molecular biology and microbiology, genes from different sources are recombined into a new gene expression host, so that the protein product with biological activity can be produced in large quantities. The gene engineering technology provides a powerful means for the research of the structure and the function of the gene, and is one of the most widely applied technical means in the field of molecular biology at present.
Plasmodium falciparum (Plasmodium falciparum) has become the most dangerous Plasmodium because of its high mortality rate and resistance to widespread antimalarial drugs, and is predominant in the world in continental africa where malaria is the most severe. The main causes of severe malaria morbidity and mortality from plasmodium falciparum infection are severe anemia due to plasmodium exponential growth causing infected erythrocytosis, blockage of the microvascular vasculature due to adhesion of mature plasmodium falciparum infected erythrocytes to microvascular endothelial cells, and obstruction of blood flow due to rosettes formed by infected and uninfected erythrocytes. Among its pathogenic mechanisms, the RIFIN proteins (p. falciparum-encoded recombinant antibodies of polypeptides) of the family of variant surface antigens play an important role in mediating adhesion of infected erythrocytes and rosette formation in the microvascular vasculature, thereby blocking blood flow and blocking blood vessels leading to severe malaria. The expression of RIFIN protein on the surface of infected erythrocytes is one of important immune targets, but the RIFIN protein can escape from the attack of the immune system due to the polygenic and genetic polymorphism of the repeatedly scattered gene family rif (recurrent intermittent family). Meanwhile, the combination of RIFIN protein and immune cell surface inhibitory receptor leukocyte immunoglobulin-like receptor B1(leukocyte immunoglobulin receptor B1, LILRB1), leukocyte-associated immunoglobulin-like receptor 1(leukocyte-associated immunoglobulin-like receptor 1, LAIR1) and the like can down-regulate immune response to achieve the purpose of immune evasion.
In recent years, with the progress of the research on the molecular mechanism of plasmodium falciparum, the development of vaccines capable of inducing effective protective immunity has become a key to the prevention and implementation of malaria elimination programs. The RIFIN proteins of the variant surface antigen family may also be important biological detection and malaria vaccine candidates.
Disclosure of Invention
The invention aims to provide a construction, preparation and function verification method of plasmodium falciparum RIFIN recombinant protein coded by a plasmodium falciparum RIFIN gene PF3D7_0833100, and the construction, preparation and function verification method of the plasmodium falciparum RIFIN recombinant protein coded by the plasmodium falciparum RIFIN gene PF3D7_0833100 aim to solve the technical problem of poor effect on treating plasmodium falciparum infection in the prior art.
The invention provides a plasmodium falciparum RIFIN recombinant protein coded by a plasmodium falciparum RIFIN gene PF3D7_0833100, which is named as PfRIFIN-54, the gene sequence of the recombinant protein is shown as SEQ ID No.1, and the amino acid sequence of the recombinant protein is shown as SEQ ID No. 4.
The invention also provides a recombinant plasmid containing the plasmodium falciparum RIFIN gene PF3D7_ 0833100.
The invention also provides a protein chip containing the plasmodium falciparum RIFIN protein, and the amino acid sequence of the protein chip is shown as SEQ ID No. 4.
The invention also provides a specific primer for PCR amplification of the plasmodium falciparum RIFIN protein gene, wherein the upstream sequence of the specific primer is shown as SEQ ID NO: 2 is shown in the specification; the downstream sequence is shown as SEQ ID NO: 3, respectively.
The invention also provides a preparation method of the plasmodium falciparum RIFIN recombinant protein coded by the plasmodium falciparum RIFIN gene PF3D7_0833100, which comprises the following steps:
1) the specific primer used for the plasmodium falciparum RIFIN protein gene is used for PCR amplification of the plasmodium falciparum RIFIN gene segment, and the sequence of the obtained plasmodium falciparum RIFIN gene segment is shown as SEQ ID No. 1;
2) connecting the gene fragment obtained in the step (1) with a vector pEU-E01-His-N2 to construct and obtain a recombinant plasmid pEU-E01-His-N2-PfRIFIN-54, respectively transferring the recombinant plasmid into competent escherichia coli E.coli DH5 alpha, and verifying and confirming the obtained recombinant strain through PCR and agarose gel electrophoresis;
3) inoculating the recombinant strain obtained in the step (2) and taking pEU-E01-His-N2 as a vector into an LB liquid culture medium, and culturing at 37 ℃ and 200rpm for 12 h;
4) extracting plasmids from the bacterial liquid obtained in the step (3) by using a kit to obtain a large amount of recombinant plasmids pEU-E01-His-N2-PfRIFIN-54;
5) and (4) expressing the protein obtained in the step (4) in a wheat germ cell-free protein expression system to obtain plasmodium falciparum RIFIN protein PfRIFIN-54, and detecting the expressed protein by Western Blot (WB).
Further, in step 1), designing SEQ ID NO: 2 and SEQ ID NO: 3 or the complementary strand thereof is used as a primer, total DNA of plasmodium falciparum is extracted, and PCR amplification is carried out by taking the total DNA as a template; the PCR amplification reaction condition is pre-denaturation at 98 ℃ for 2.0 min; denaturation at 98 ℃ for 20sec, annealing at 55 ℃ for 30sec, extension at 72 ℃ for 1.0min, 35 cycles; extension at 72 ℃ for 10min and final storage at 4 ℃.
Further, in the step 2), the plasmid vector pEU-E01-His-N2 is subjected to double enzyme digestion by Xho I and BamH I, and is recovered and purified; performing In-Fusion connection according to the concentration of the PCR product obtained In the step 1) and the enzyme digestion fragment of the plasmid vector to construct a recombinant plasmid pEU-E01-His-N2-PfRIFIN-54 for prokaryotic expression of the RIFIN encoding gene of the plasmodium falciparum; transforming the recombinant plasmid into escherichia coli DH5 alpha competent cells by a heat shock method, coating the cells on an LB agar plate containing ampicillin after culturing, randomly selecting bacterial colonies on the plate, and carrying out PCR identification and sequencing identification on a bacterial liquid after shaking culture;
further, in step 3): inoculating the Escherichia coli DH5a recombinant strain containing pEU-E01-His-N2-PfRIFIN-54 sequenced in the step 2) into an LB liquid culture medium, culturing at 37 ℃ and 200rpm for 12h, collecting the strain, extracting the recombinant plasmid pEU-E01-His-N2-PfRIFIN-54 by using a kit, and placing the obtained DNA at-30 ℃ or-80 ℃ for later use;
further, in step 4): expressing the recombinant plasmid pEU-E01-His-N2-PfRIFIN-54 obtained in the step 3) and a malt germ cell-free expression system to obtain a plasmodium falciparum RIFIN protein PfRIFIN-54, and identifying a protein expression result by using Western-blot.
The invention also provides application of the plasmodium falciparum RIFIN recombinant protein coded by the plasmodium falciparum RIFIN gene PF3D7_0833100 in preparing a kit for detecting severe or non-severe plasmodium falciparum infected patients.
The plasmodium falciparum RIFIN protein is named as PfRIFIN-54, is derived from plasmodium falciparum (P.falciparum 3D7), has the nucleotide sequence length of 1044bp, and is shown as SEQ ID No. 1; the amino acid sequence has a length of 347aa and is shown as SEQ ID No. 4.
The invention obtains a gene sequence of PfRIFIN-54 through a plasmodium falciparum genome sequence, obtains a PfRIFIN-54 gene fragment by utilizing specific primer PCR, thereby constructing a recombinant expression plasmid pEU-E01-His-N2-PfRIFIN-54, and performs serum immune reaction through a protein chip to perform functional verification on the PfRIFIN-54.
Compared with the prior art, the invention has the advantages of positive and obvious technical effect. Compared with the control PfMSP1-42, the protein of the invention not only has better ability of specifically recognizing the serum of the patient infected with plasmodium falciparum, but also shows obvious difference on the serum immunoreaction of severe and non-severe patients infected with plasmodium falciparum, and the positive rate of the immunoreaction of the serum of the severe patients is obviously lower than that of the serum immunoreaction of the non-severe patients.
Drawings
FIG. 1: schematic diagram of PCR amplification result of PfriFIN-54 gene fragment, wherein: m is DL,2000DNA Leader (Takara); lane 1 shows the PfRIFIN-54 gene fragment.
FIG. 2: schematic representation of colony PCR results for recombinant strain e.coli DH5 α/pEU-E01-His-N2-PfRIFIN-54, wherein: m is DNA marker (DL,2000DNA Leader, Takara); lanes 1-4 are E.coli DH5 α/pEU-E01-His-N2-PfRIFIN-54 recombinant strains.
FIG. 3: PF3D 7-0833100 cell-free expression of western-blot results are shown schematically, in which: m is Protein marker (Page Ruler Protein Ladder 26616, Thermo).
FIG. 4: schematic diagram of antibody serum immunoreaction analysis results, wherein: SMG represents the serum sample antibody response of severe patients with falciparum malaria, and NMG represents the serum sample antibody response of non-severe patients with falciparum malaria.
Detailed Description
The following examples are intended to illustrate the invention only and are not intended to limit the scope of the invention. The experimental procedures, in which specific conditions are not specified in the examples, are generally carried out under conventional conditions or conditions recommended by the manufacturers.
EXAMPLE 1 preparation of Plasmodium falciparum RIFIN protein PfRIFIN-54
1 Material
1.1 Plasmodium falciparum genomic DNA
Is derived from Plasmodium falciparum PF3D 7.
1.2 host strains Escherichia coli DH5 alpha, plasmid pEU-E01-His-N2 from Tiangen Biochemical technology limited and Nippon, CellFree Sciences company, respectively.
1.3 Primary reagent and tool enzymes
2 method
2.1 amplification and cloning of Plasmodium falciparum RIFIN protein PfRIFIN-54 Gene
2.1.1 PCR amplification of Plasmodium falciparum RIFIN protein PfRIFIN-54 Gene
According to the Sequence (shown in SEQ ID NO. 1) of plasmodium falciparum RIFIN protein PfRIFIN-54 gene (PF3D7_0833100GeneID:9221922, NCBI Reference Sequence: XM _002808685.1), a pair of specific primers are designed by using primer design software of Shanghai Yingjun Biotechnology limited company, wherein the lower case letters in the specific primers are respectively 15 bases which are homologous with the tail end of a digestion vector, and the single underline indicates that the digestion sites are respectively Xho I and BamH I digestion sites. The specific primer is synthesized by Shenzhen Hua Dagen Co. The primer sequences are as follows:
upstream: 5' -gggcggatatctcgagCAAATTCCATCCATCACACC-3' (shown in SEQ ID NO: 2);
downstream: 5' -gcggtacccgggatccttaTTCTTCTAATAGTTTTATATATTG-3' (shown in SEQ ID NO: 3)
PCR amplification was performed using Plasmodium falciparum genomic DNA as a template. The reaction condition is pre-denaturation at 98 ℃ for 2.0 min; denaturation at 98 ℃ for 20 sec; annealing at 55 deg.C for 30sec, extending at 72 deg.C for 1.0min, and performing 35 cycles; extending for 10min at 72 ℃; storing at 4 ℃. Phusion high fidelity DNA polymerase was purchased from Finnzymes under Thermo Scientific flag. The reaction system is 20.0 mul, in particular to 4.0 mul of 5x Phusion HF Buffer (Phusion high fidelity Buffer); 0.4. mu.l of 10mM dNTPs; p F (upstream primer) (10. mu.M each) 1. mu.l; p R (downstream primer) (10. mu.M each) 1. mu.l; template DNA (DNA Template) 1. mu.l; phusion DNA Polymerase (Phusion DNA Polymerase) 0.2. mu.l; nuclean-free water (Nuclease-free water) 12.4. mu.l. (the PCR system reagents are all from Phusion Hi-Fi DNA polymerase kit from Finnzymes under Thermo Scientific flag)
2.1.2 recombinant plasmid expressed by Plasmodium falciparum RIFIN protein PfRIFIN-54
Construction and identification of pEU-E01-His-N2-PfRIFIN-54
The plasmid pEU-E01-His-N2 is cut by endonuclease Xho I and BamH I respectively, and the PCR product and the concentration of the cut plasmid pEU-E01-His-N2 are connected by an In-Fusion cloning method to construct a recombinant plasmid pEU-E01-His-N2-PfriFIN-54 of the plasmodium falciparum RIFIN protein PfriFIN-54 coding gene without cell expression. The method comprises the following specific steps:
1) mu.l of PCR reaction product was taken and 2. mu.l of cloning Enhancer (cloning promoter) purchased from Clontech was added;
2) placing the mixture in the previous step into a PCR instrument, incubating for 15min at 37 ℃ and incubating for 15min at 80 ℃;
3) the PCR product was ligated with the digested pEU-E01-His-N2 empty plasmid using the In-Fusion cloning method. The reaction condition is incubation for 15min at 37 ℃; incubating at 50 deg.C for 15 min; taking out and putting on ice for conversion and use. The In-Fusion enzyme was purchased from Clontech. The Reaction system (reagents used were all from an In-Fusion enzyme kit, available from Clontech) was 10. mu.l, specifically 5 XIn-Fusion Reaction Buffer (In-Fusion Reaction Buffer) 2. mu.l; 1. mu.l of In-Fusion Enzyme; vector 2. mu.l (. about.100 ng); insert 2. mu.l; dH2O (distilled water) (if necessary) 3. mu.l; the joined recombinant plasmid
pEU-E01-His-N2-PfRIFIN-54 was transformed into E.coli DH5 alpha competent cells by heat shock method, cultured and plated on ampicillin-containing (Amp)+100 ug/ml) on an LB agar plate, randomly picking colonies on the plate, culturing the colonies by shaking, and performing colony PCR identification and sequencing identification. The bacterial sample with the correct colony PCR identification is sent to Huada Gene company for sequencing analysis.
The recombinant strain E.coli DH5 alpha/pEU-E01-His-N2-PfRIFIN-54 which is correctly sequenced is preserved for later use.
2.2 expression and validation of recombinant plasmid of Plasmodium falciparum RIFIN protein PfRIFIN-54 in wheat germ cell-free (WGCF) protein expression System
2.2.1 preparation of recombinant plasmid pEU-E01-His-N2-PfRIFIN-54
The recombinant Plasmid pEU-E01-His-N2-PfRIFIN-54 is extracted by using a QIAGEN Plasmid middle extraction Kit (25), and the specific steps are as follows:
1) the recombinant bacterium containing the plasmid pEU-E01-His-N2-PfRIFIN-54 was inoculated into 50ml LB liquid medium (Amp)+100. mu.g/ml) at 37 ℃ and 200rpm for 12 hours;
2) and (3) collecting thalli: centrifuging at 4 deg.C and 6000Xg for 15min, and removing supernatant;
3) resuspend the cells with 4ml Buffer P1;
4) adding 4ml Buffer P2, inverting for 4-6 times to mix the solution completely, standing at room temperature for 5min (changing Lyseblue reagent solution into blue);
5) adding 4ml of precooled Buffer P3, reversing the upper part and the lower part for 4 to 6 times to completely mix, and standing on ice for 15min (the blue color disappears);
6) centrifuging at 4 deg.C for 30min to obtain supernatant with impurities, and centrifuging for 15 min;
7) the QIAGEN-tip column was equilibrated with 4ml Buffer QBT to allow the liquid to drain naturally by gravity;
8) pouring the supernatant obtained in the step 5 into a balanced column, and draining the supernatant by natural flow (impurities are not poured);
9) the column was washed with 2 × 10ml Buffer QC and drained (2 washes, 10ml each);
10) eluting the DNA on the column into a clean 15ml centrifuge tube by using 5ml of Buffer QF, and if the DNA is more than 45kb, heating the elution Buffer to 65 ℃ in advance to improve the elution efficiency;
11) DNA precipitation: adding 3.5ml isopropanol into the eluted DNA solution, mixing well, centrifuging at no less than 15000Xg at 4 deg.C for 30min, and carefully removing the supernatant;
12) washing the DNA precipitate with 2ml 70% ethanol, centrifuging at no less than 15000Xg at 4 deg.C for 15min, and carefully removing the supernatant;
13) air-dried (left for 5-10min), and then resuspended with 200. mu.l of nucleic-Free Water, the obtained DNA was assayed for concentration using NanODROP 2000(Thermo), and the remaining DNA was left at-30 ℃ or-80 ℃ for further use.
2.2.2 expression of recombinant plasmid of Plasmodium falciparum RIFIN protein PfRIFIN-54 in Wheat Germ Cell Free (WGCF) expression System
The method comprises the following specific steps:
1) 10 mul of transcription system, adding pEU-E01-His-N2-PfRIFIN-54 plasmid with the final concentration of 100 ng/mul, 0.125 mul of RNase inhibitor, 0.125 mul of SP6 RNase, 25mmol NTP mix 1 mul, 5x transcription Buffer 2 mul, adding Nuclear-Free Water to 10 mul, and standing at 37 ℃ for 6 h;
2) expression (translation) system: adding 10 μ l of 1) transcription system into 10 μ l WEPRO and 1.6 μ l CK enzyme (diluted), mixing, adding into 206 μ l SubMix, and standing at 15 deg.C for 20 h;
3) after the expression is finished, mixing evenly, identifying by Western-blot, and keeping the residual protein at-80 ℃ for later use.
2.2.3 validation of Plasmodium falciparum RIFIN protein PfRIFIN-54
The method comprises the following specific steps:
western-blot identification was performed on the Plasmodium falciparum RIFIN protein PF3D 7-0833100 expressed in a malt germ cell-free (WGCF) expression system. The method comprises the following specific steps:
1) after SDS-PAGE electrophoresis, the plasmodium falciparum RIFIN protein PfRIFIN-54 is electrically transferred to a PVDF membrane (Millipore);
2) cutting the membrane into strips, placing in 5% skimmed milk powder solution (3% BSA) for blocking for 1h (dissolving with TBST), rinsing PVDF membrane with TBST for 5min each time for 3 times;
3) diluting primary antibody (Penta, His, Ab) and TBST according to a certain ratio (1:2000), placing on a shaking table for reacting for 1h, and rinsing the PVDF membrane with TBST for 5min each time for 3 times;
4) diluting the secondary antibody (Goat-a-Mouse IgG-HRP) and TBST according to a certain ratio (1:2000), placing on a shaking table for reacting for 1h, and rinsing the PVDF membrane with TBST for 5min each time for 3 times;
5) the color developing solution (DAB: PBS: 30% H) is prepared according to the proportion2O22mg:3ml:0.9 mul), placing the rinsed PVDF membrane into a tray containing a color development solution for color development, immediately rinsing with PBS after a target strip appearsThe reaction was stopped and blotted dry with filter paper.
3 results
3.1 amplification and cloning of Plasmodium falciparum RIFIN protein PfRIFIN-54 Gene
3.1.1 PCR amplification of Plasmodium falciparum RIFIN protein PfRIFIN-54 Gene
The plasmodium falciparum genomic DNA is used as a template to carry out PCR amplification, and a target fragment (shown in figure 1) with 1044bp consistent with the expected length is amplified, which indicates that the PfRIFIN-54 gene is successfully amplified.
3.1.2 recombinant plasmid for Plasmodium falciparum RIFIN protein PfRIFIN-54 expression
Construction and identification of pEU-E01-His-N2-PfRIFIN-54
The target gene fragment is connected with the restriction enzyme pEU-E01-His-N2 no-load plasmid through an In-Fusion cloning method to construct a recombinant plasmid pEU-E01-His-N2-PfRIFIN-54, and the colony PCR result (shown In figure 2) and the sequencing result are consistent with the size of the target gene fragment through colony PCR and sequencing identification, which indicates that the recombinant plasmid is successfully constructed.
3.2 expression and validation of recombinant plasmid of Plasmodium falciparum RIFIN protein PfRIFIN-54 in wheat germ cell-free (WGCF) protein expression System
Western blot analysis results of the Plasmodium falciparum RIFIN protein PfRIFIN-54 expressed in a wheat germ cell-free (WGCF) protein expression system show that the Plasmodium falciparum RIFIN protein PfRIFIN-54 can be specifically recognized by an anti-His antibody, and a single and obvious band appears on a PVDF membrane (see figure 3).
Example 2 preparation of Plasmodium falciparum RIFIN protein PfRIFIN-54 protein chip and serum immunoreaction
1 Material
1.1 preparation of protein chip plectrum and rail, from CapitalBio of Beijing.
1.2 human serum samples of falciparum malaria patients and normal humans, collected from the malaria endemic area.
1.3 Alexa Fluor 546goat anti-human IgG from Invitrogen.
2 method
2.1 preparation of chip of protein PfRIFIN-54 of Plasmodium falciparum RIFIN
1) The crude protein PfRIFIN-54 was mixed with protein spot buffer (CapitalBio, beijing) at a ratio of 1:1 and 50 μ Ι _ of the protein mixture was transferred to a 384 well plate;
2) pf MSP1-42 as positive control, and wheat germ expression system without plasmid vector as negative control;
3) spotting was performed using a 48Smart array (CapitalBio, Beijing) protein chip spotter.
2.2 Plasmodium falciparum RIFIN protein PF3D7_0833100 protein chip serum immune response
Multiple sera from severe patients (SMG), non-severe patients (NMG), and normal human sera (NCG) infected with plasmodium falciparum were prepared as positive and negative serum controls, respectively. The method comprises the following specific steps:
1) blocking the protein chip obtained in 2.1 with 3% BSA (PBS) at 4 ℃ overnight, incubating at 37 ℃ for 1h, centrifuging at 1000-1500rpm at 4 ℃ for 3min, and spin-drying the blocking solution;
2) washing with PBS-T for 3 times, each time for 3min, centrifuging at 1000-1500rpm at 4 deg.C for 3min, and spin-drying;
3) incubating with primary antigen (falciparum malaria human serum and normal human serum (1:100 (adjustable) and PBS dilution)) at 37 deg.C for 1h, centrifuging at 1000-;
4) washing with PBS-T for 3 times, each time for 3min, centrifuging at 1000-1500rpm at 4 deg.C for 3min, and spin-drying;
5) diluting the secondary antibody (Alexa Fluor 546 gat anti-human IgG) with PBS (1:200), incubating at 37 ℃ for 1h, centrifuging at 1000 ℃ and 1500rpm at 4 ℃ for 3min, and spin-drying;
6) washing with PBS-T for 3 times, each time for 3min, centrifuging at 1000-1500rpm at 4 deg.C for 3min, and spin-drying;
7) the protein chips were scanned at 532nm using a LuxScan HT24 microarray scanner (CapitalBio, Beijing).
Statistical analysis of data
Protein chip fluorescence data were extracted using Microarray Image Analysis SpotData-Ver2.0(CapitalBio, Beijing) software, and experimental data were collated and statistically analyzed using Excel spreadsheet processing software and GraphPad Prism-Ver7.0.
4 results
The detection of IgG of a protein chip is respectively carried out on the serum of severe patients and non-severe patients infected by plasmodium falciparum and the normal human serum by using the plasmodium falciparum RIFIN protein PfRIFIN-54 (as shown in figure 4), the result shows that the protein shows obvious difference on the serum immunoreaction of severe patients and non-severe patients infected by plasmodium falciparum, as shown in figure 4, compared with the control PfMSP1-42, the protein not only has higher immunological recognition on the serum of patients infected by plasmodium falciparum, but also shows obvious difference on the serum immunoreaction of severe patients and non-severe patients infected by plasmodium falciparum, and the positive rate of the immunoreaction on the serum of severe patients is obviously lower than that of the serum immunoreaction of non-severe.
Discussion of 5
The invention takes plasmodium falciparum genome DNA as a template, adopts an In-Fusion cloning method to successfully clone and obtain recombinant plasmids constructed by plasmodium falciparum RIFIN protein PfRIFIN-54 and a cell-free expression vector pEU-E01-His-N2, obtains PfRIFIN-54 recombinant protein through a wheat germ cell-free (WGCF) protein expression system, and is proved by Western-blot identification to be specifically identified by an anti-His antibody, a clear band appears at 38.7KDa, and the molecular weight of the band is consistent with that of a target protein.
The gene engineering technology provides convenience for developing a preparation and detection method of recombinant antigen for detecting human serum antibody, and the protein chip technology provides a simple, convenient and effective method for researching the interaction between protein and protein, even the interaction between DNA-protein and RNA-protein, and screening protein targets of drug action. The invention discloses the obvious immunological difference of the protein in severe patients and non-severe patients, and the positive rate of the immune response of the serum of the severe patients is obviously lower than the positive rate of the immune response of the serum of the non-severe patients. In conclusion, the protein of the invention participates in the immune evasion process in severe plasmodium falciparum infection, so that the immune system of a human body cannot recognize the antigen and cannot generate antibodies, thereby leading the red blood cells infected with the plasmodium falciparum to generate immune evasion. Therefore, the invention can be used as the basis for researching the immune evasion mechanism of the plasmodium falciparum, provides the basis for further researching the pathogenic mechanism of the plasmodium falciparum, and has important application value in the aspects of elimination and control of the malaria.
Although the embodiments of the present invention have been described and illustrated, it should be understood that they have been presented by way of example only, and not limitation, and that various changes and modifications can be effected therein by one skilled in the art without departing from the spirit and scope of the invention as defined in the appended claims.
Sequence listing
<110> Chinese disease prevention and control center for prevention and control of parasitic diseases institute (national center for research on tropical diseases)
<120> construction, preparation and application of plasmodium falciparum RIFIN recombinant protein PfRIFIN-54
<160> 4
<170> SIPOSequenceListing 1.0
<210> 1
<211> 1044
<212> DNA
<213> Plasmodium falciparum
<400> 1
atgcaaattc catccatcac accacaccat acaccaacta tcaggttatt atgcgaatgc 60
gaattatatg tgcctaattg tgacaacgat cctgaaatga aaagggtgat gcaacaattt 120
catgatcgta caacacaaag gtttcaagaa tacgatgaaa gattgcaaga aagacgacaa 180
atatgtaaag ataaatgtga taaggaaatc caaaaaatta ttttaaaaga taaattagaa 240
aaagaattaa tggacaaatt tgctacgtta gacacggata tacaaagtga cgccattcca 300
acatgtattt gcgaaaaatc gttagcagat aaagtggaaa gaggatgctt gagatgtggt 360
tatggtctag gaagtgttgc accaatgatt ggattaactg gttcagttgc tgtaaatgtg 420
tggaaaactg cagaacttgc agcggctatg gaattagcta aacaagcagg tgctgcggcc 480
ggtattaaag caggacattt ggcgggtact aaagttgtta ttgatcaatt acacacattg 540
ggtatatact ttgtaggtaa taaacaattg gaaacaatta ttgatgtaac aaattatatg 600
aatgtgtctg tcattaatga taatgtttat tctcattata tcacgtcatg tacacctagt 660
gttgttaatg gtcgccctgt cggtactttt aaatttagtg gtcctgtttg caatttggtt 720
cagccaaatc atcaaggtat atgggataga agtttagcac aagctattat aaaaaaaaag 780
gtagaagaag ctgttgcaga aggtacacaa gctgctgaaa ccgaagctgc tagggtgact 840
gccactaaaa cagcagcatt tgaagcaaaa aacatagccg aagtagaagc tgcaactact 900
tcctactata ctcctataat agcatccatc gttgcaatag taatcatagt tttaattatg 960
gtgataatat ataagatttt acgttatcga cgaaaaaaaa aaatgaagaa aaaactccaa 1020
tatataaaac tattagaaga atag 1044
<210> 2
<211> 36
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 2
gggcggatat ctcgagcaaa ttccatccat cacacc 36
<210> 3
<211> 43
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 3
gcggtacccg ggatccttat tcttctaata gttttatata ttg 43
<210> 4
<211> 347
<212> PRT
<213> Plasmodium falciparum
<400> 4
Met Gln Ile Pro Ser Ile Thr Pro His His Thr Pro Thr Ile Arg Leu
1 5 10 15
Leu Cys Glu Cys Glu Leu Tyr Val Pro Asn Cys Asp Asn Asp Pro Glu
20 25 30
Met Lys Arg Val Met Gln Gln Phe His Asp Arg Thr Thr Gln Arg Phe
35 40 45
Gln Glu Tyr Asp Glu Arg Leu Gln Glu Arg Arg Gln Ile Cys Lys Asp
50 55 60
Lys Cys Asp Lys Glu Ile Gln Lys Ile Ile Leu Lys Asp Lys Leu Glu
65 70 75 80
Lys Glu Leu Met Asp Lys Phe Ala Thr Leu Asp Thr Asp Ile Gln Ser
85 90 95
Asp Ala Ile Pro Thr Cys Ile Cys Glu Lys Ser Leu Ala Asp Lys Val
100 105 110
Glu Arg Gly Cys Leu Arg Cys Gly Tyr Gly Leu Gly Ser Val Ala Pro
115 120 125
Met Ile Gly Leu Thr Gly Ser Val Ala Val Asn Val Trp Lys Thr Ala
130 135 140
Glu Leu Ala Ala Ala Met Glu Leu Ala Lys Gln Ala Gly Ala Ala Ala
145 150 155 160
Gly Ile Lys Ala Gly His Leu Ala Gly Thr Lys Val Val Ile Asp Gln
165 170 175
Leu His Thr Leu Gly Ile Tyr Phe Val Gly Asn Lys Gln Leu Glu Thr
180 185 190
Ile Ile Asp Val Thr Asn Tyr Met Asn Val Ser Val Ile Asn Asp Asn
195 200 205
Val Tyr Ser His Tyr Ile Thr Ser Cys Thr Pro Ser Val Val Asn Gly
210 215 220
Arg Pro Val Gly Thr Phe Lys Phe Ser Gly Pro Val Cys Asn Leu Val
225 230 235 240
Gln Pro Asn His Gln Gly Ile Trp Asp Arg Ser Leu Ala Gln Ala Ile
245 250 255
Ile Lys Lys Lys Val Glu Glu Ala Val Ala Glu Gly Thr Gln Ala Ala
260 265 270
Glu Thr Glu Ala Ala Arg Val Thr Ala Thr Lys Thr Ala Ala Phe Glu
275 280 285
Ala Lys Asn Ile Ala Glu Val Glu Ala Ala Thr Thr Ser Tyr Tyr Thr
290 295 300
Pro Ile Ile Ala Ser Ile Val Ala Ile Val Ile Ile Val Leu Ile Met
305 310 315 320
Val Ile Ile Tyr Lys Ile Leu Arg Tyr Arg Arg Lys Lys Lys Met Lys
325 330 335
Lys Lys Leu Gln Tyr Ile Lys Leu Leu Glu Glu
340 345
Claims (10)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011460834.2A CN112592395A (en) | 2020-12-11 | 2020-12-11 | Construction, preparation and application of plasmodium falciparum RIFIN recombinant protein PfRIFIN-54 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011460834.2A CN112592395A (en) | 2020-12-11 | 2020-12-11 | Construction, preparation and application of plasmodium falciparum RIFIN recombinant protein PfRIFIN-54 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112592395A true CN112592395A (en) | 2021-04-02 |
Family
ID=75192523
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011460834.2A Pending CN112592395A (en) | 2020-12-11 | 2020-12-11 | Construction, preparation and application of plasmodium falciparum RIFIN recombinant protein PfRIFIN-54 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112592395A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113150101A (en) * | 2021-04-23 | 2021-07-23 | 中国疾病预防控制中心寄生虫病预防控制所(国家热带病研究中心) | Construction, preparation and application of plasmodium falciparum RIFIN recombinant protein PfRIFIN-55 |
| CN115043923A (en) * | 2022-06-24 | 2022-09-13 | 中国疾病预防控制中心寄生虫病预防控制所(国家热带病研究中心) | Plasmodium falciparum RIFIN polypeptide 8-RIFIN and derivative product and application thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000025728A2 (en) * | 1998-11-05 | 2000-05-11 | United States Government As Represented By The Secretary Of The Navy | Chromosome 2 sequence of the human malaria parasite plasmodium falciparum and proteins of said chromosome useful in anti-malarial vaccines and diagnostic reagents |
| US20040202667A1 (en) * | 2002-03-04 | 2004-10-14 | Daniel Carucci | Antigens and their use as diagnostics and vaccines against species of plasmodium |
| CN105940115A (en) * | 2013-11-15 | 2016-09-14 | 巴斯德研究所 | Molecular markers of artemisinin resistance in Plasmodium falciparum |
-
2020
- 2020-12-11 CN CN202011460834.2A patent/CN112592395A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000025728A2 (en) * | 1998-11-05 | 2000-05-11 | United States Government As Represented By The Secretary Of The Navy | Chromosome 2 sequence of the human malaria parasite plasmodium falciparum and proteins of said chromosome useful in anti-malarial vaccines and diagnostic reagents |
| US20040202667A1 (en) * | 2002-03-04 | 2004-10-14 | Daniel Carucci | Antigens and their use as diagnostics and vaccines against species of plasmodium |
| CN105940115A (en) * | 2013-11-15 | 2016-09-14 | 巴斯德研究所 | Molecular markers of artemisinin resistance in Plasmodium falciparum |
Non-Patent Citations (4)
| Title |
|---|
| GENBANK数据库: "Plasmodium falciparum 3D7 rifin(PF3D7_0833100), partial mRNA Accession No:XM_002808685.1", 《GENBANK数据库》 * |
| KASSEGNE ET AL: "Study roadmap for high-throughput development of easy to use and affordable biomarkers as diagnostics for tropical diseases: a focus on malaria and schistoomiasis", 《INFECTIOUS DISEASES OF POVERTY》 * |
| MOHAMED S. ABDEL-LATIF ET AL: "Recognition of Variant Rifin Antigens by Human Antibodies Induced during Natural Plasmodium falciparum Infections", 《INFECTION AND IMMUNITY》 * |
| SUCHI GOEL ET AL: "RIFINs are adhesins implicated in severe Plasmodium falciparum", 《NATURE MEDICINE》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113150101A (en) * | 2021-04-23 | 2021-07-23 | 中国疾病预防控制中心寄生虫病预防控制所(国家热带病研究中心) | Construction, preparation and application of plasmodium falciparum RIFIN recombinant protein PfRIFIN-55 |
| CN115043923A (en) * | 2022-06-24 | 2022-09-13 | 中国疾病预防控制中心寄生虫病预防控制所(国家热带病研究中心) | Plasmodium falciparum RIFIN polypeptide 8-RIFIN and derivative product and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112111006B (en) | Antibody for resisting bovine sarcoidosis virus, detection test paper and kit | |
| CN105384803A (en) | Schistosoma japonicum katsurada recombinant protein SjSAPLP4 as well as encoding gene and application thereof | |
| CN113637056B (en) | A kit for differentiating Brucella bovis from other Brucella species | |
| CN112592395A (en) | Construction, preparation and application of plasmodium falciparum RIFIN recombinant protein PfRIFIN-54 | |
| CN110628776B (en) | A gene encoding allergenic protein of Scylla simulans and its application | |
| CN106866825B (en) | Silkworm internal reference protein GAPDH polyclonal antibody and preparation method thereof | |
| CN110054687B (en) | Grass carp ATG12 polyclonal antibody and preparation method thereof | |
| CN112358536B (en) | Scy p 1 derivative of scylla paramamosain sensitization protein and application thereof | |
| US9051665B2 (en) | Method for screening biomolecules | |
| CN101293919B (en) | Syphilis spirochete membrane antigen with shortened expression and uses thereof | |
| CN109306008B (en) | Single-chain antibody of swine-origin anti-classical swine fever virus and preparation method thereof | |
| CN113150101A (en) | Construction, preparation and application of plasmodium falciparum RIFIN recombinant protein PfRIFIN-55 | |
| CN108982847B (en) | Indirect ELISA (enzyme-linked immunosorbent assay) detection method for duck reovirus causing duck spleen necrosis | |
| CN103570817B (en) | Plasmodium vivax PvMSP1 recombinant antigenic protein as well as preparation method and application thereof | |
| Wang et al. | Nucleotide sequence, serology and symptomatology suggest that vanilla necrosis potyvirus is a strain of watermelon mosaic virus II | |
| CN111363758A (en) | Preparation and application of polyclonal antibody of major capsid protein of epinephelus neocalifornicus iridovirus | |
| CN113527463B (en) | Application of IFITM3 protein-related substances in the preparation of medicines for diseases caused by avian reovirus | |
| CN112301044B (en) | A kind of polyclonal antibody of NbAPX3 gene of Bunsen cigarette and its preparation method and application | |
| CN111518180B (en) | Tuberculosis candidate vaccine fusion protein | |
| CN103074344A (en) | Preparation method and application of taenia pisiformis 18kDa antigen | |
| CN107603979A (en) | A kind of startup increment gene of high efficient expression foreign protein and its application | |
| CN108588096B (en) | Babesia orientalis spheroid protein gene 4 and its encoded protein | |
| CN114106170B (en) | Amino acid sequence of anti-field halichondrin single-chain antibody and expression vector thereof | |
| CN111850003A (en) | A recombinantly expressed Pasteurella multocida thiamine periplasmic binding protein and its application | |
| CN117402884B (en) | Gene separated from sinonovacula constricta and having coagulase activity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |